Loading...
NPI 1942378708 · San Juan, PR · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratorio Clinico Noy Inc is a clinical medical laboratory provider located in San Juan, Puerto Rico. This profile covers 32 Medicare and 61 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratorio Clinico Noy Inc |
| Address | 239 Ave Arterial Hostos |
| City | San Juan |
| State | PR |
| ZIP | 00918 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 1, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $9.9M |
| Medicare | $76.1K |
This provider is effectively Medicaid‑dominated: lifetime Medicaid revenue is $9.9M compared with total Medicare revenue of $76.1K, indicating that the vast majority of reported billing activity and dollar volume is on the Medicaid side rather than Medicare. Analysts should treat Medicaid performance as the primary driver of this lab’s business footprint.
Revenue concentration is high on a small set of molecular/STI tests for both payers: the top 3 Medicare codes account for 55.7% of this provider's total Medicare revenue, while the top 3 Medicaid codes account for 62.9% of this provider's total Medicaid revenue. On Medicare those top codes are 87624 ($24.1K), 87661 ($8.9K), and 87491 ($8.6K); on Medicaid they are dominated by 87661 ($5M), 87624 ($614.8K), and 81513 ($554K).
The code mix identifies a specialty molecular diagnostics lab focused on sexual and reproductive infection testing: high‑volume NAAT/amplicon codes such as 87661 (Trichomonas), 87624 (HPV), 87491 (Chlamydia), and 87591 (Neisseria gonorrhoeae) are among the largest revenue contributors. The presence of algorithmic BV testing under 81513 and Mycoplasma testing 87563 further supports that the lab’s service line is oriented toward women’s health and STI molecular panels rather than only routine chemistry/hematology.
Within the state Medicaid market this lab is a clear market leader for several core services: 87661 (155.4K claims, $5M revenue) ranks #1 of 11 providers in-state (100th percentile; labeled notably above typical state volume), 81513 ($554K) ranks #1 of 3, 87481 ($486.2K) ranks #1 of 5, and culture work 87070 (56.3K claims, $450.5K) ranks #1 of 67 with an explicit designation as an extreme outlier. These rankings indicate the lab is a dominant in-state supplier of molecular STI testing and certain culture services.
By contrast, the provider’s Medicare footprint is modest and broadly typical at the national level: 87624 is the largest Medicare line at $24.1K and ranks #60 of 475 (88th percentile) while 87661 and 87491 rank in the high‑70s percentiles nationally; summary commentary in the Medicare table flags these volumes as "typical, unremarkable." This suggests the lab is a strong regional/state actor for Medicaid but only a modest national participant on Medicare work.
There are clear statistical outliers in the Medicaid dataset to flag for utilization review or capacity planning: 87070 is described as an "extreme outlier, far above typical state volume" and 87661 is flagged as "notably above typical state volume," with claim counts of 56.3K and 155.4K respectively. These specific large-volume lines will disproportionately affect operational throughput, specimen logistics, and contracting leverage with payers.
Despite the specialty concentration, the lab also bills routine clinical tests at low volumes, indicating some general clinical testing capability alongside its molecular focus: Medicare lists modest revenue for 84443 (TSH, $1.6K), 80061 (lipid panel, $1.4K), 82306 (vitamin D, $1.3K) and 85025 (CBC, $1.3K), and similar small Medicaid contributions (e.g., 84443 $48.3K, 82306 $43.4K). These smaller lines suggest ancillary or referral testing services rather than core revenue drivers.
The provider has an established NPI tenure—enumerated 2006-12-01 (~20 years ago)—which supports interpretation of the observed patterns as the result of a sustained operating strategy rather than a transient reporting anomaly. Given the long enumeration and the concentrated Medicaid dominance, payer analysts should prioritize state Medicaid contract terms, capacity, and utilization for this entity when assessing network value and risk.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
32 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 710 | $30 | $24.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 260 | $30 | $8.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 250 | $30 | $8.6K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 250 | $30 | $8.6K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 60 | $140 | $8.5K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 60 | $30 | $2.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 60 | $30 | $2.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 100 | $20 | $1.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 100 | $10 | $1.4K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 50 | $30 | $1.3K |
Showing 1–10 of 32
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 32 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 155,440 | $30 | $5M |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 20,490 | $30 | $614.8K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 14,970 | $40 | $554K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 16,210 | $30 | $486.2K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 15,630 | $30 | $484.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 15,620 | $30 | $484.2K |
| 87070 | The lab analyst performs the technical lab steps to culture a specimen from any source except urine, blood, or stool. This service involves aerobic culture, which refers to the presence of oxygen.… | 56,320 | $10 | $450.5K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 14,920 | $30 | $417.8K |
| 87625 | The lab analyst performs a test to determine the presence of human papillomavirus. The provider uses nucleic acid detection for types 16 and 18, and 45 when performed. | 7,940 | $30 | $238.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 4,660 | $50 | $228.4K |
Showing 1–10 of 61
How this provider's Medicaid billing volume and revenue compare to other Puerto Rico providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Puerto Rico median
61 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 1 | 10 | 4,190 | $30 | $655.7K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 6 | 30 | 910 | $40 | $638.8K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 1 | 10 | 2,920 | $40 | $235K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1 | 10 | 2,020 | $30 | $139.7K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 1 | 10 | 2,430 | $30 | $138.4K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 206 | 650 | 1,260 | $40 | $93.7K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 2 | 10 | 760 | $40 | $76K |
| 87490 | The lab analyst performs a test for Chlamydia trachomatis using direct nucleic acid probe technique. Chlamydia trachomatis causes a common sexually transmitted disease and certain eye infections. | 9 | 70 | 150 | $20 | $71.9K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 321 | 770 | 2,520 | $20 | $65.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 48 | 590 | 1,440 | $20 | $65.4K |
Showing 1–10 of 61
Other providers in the same ZIP code as Laboratorio Clinico Noy Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.